Nanoparticles (NPs) have been widely pursued as a promising tool to increase the biodistribution of an- ti-cancer therapeutics in tumors, thereby reducing the general exposure to chemotherapy. It is generally acknowledged that defective vasculature and lymphatic systems surrounding tumors offer a selective oppor- tunity for NPs to accumulate in tumors. However, the amount delivered to tumors this way is only a small frac- tion (~5%) of the total administered NPs. This challenge may be addressed by decorating the surface of NPs using a tumor-specific ligand, but the benefit is often limited due to the heterogeneity and genetic instability of tumors. Challenges in drug delivery using NPs are aggravated by the limited penetration of NPs into tumors, due to high tissue stiffness and interstitial fluid pressure. Substantive departure from the status quo NP-based drug delivery requires a new strategy to increase the amount of NPs delivered to and retained by tumors beyond the level currently possible based on passive delivery via the so-called enhanced permeability and retention (EPR) effect or other targeting strategies. Our long term goal is to develop a new drug delivery strategy that enhances delivery of nanomedicine into solid tumors to a greater extent than currently achieved. The objective of this application is to enhance the accumulation, retention, and penetration of anti-cancer drugs into solid tumors, via synergistic application of environmentally-adaptive NPs (ENPs) and image-guided radiation-induced permeability (IGRIP). Our central hypothesis is that NPs developing cationic surface or reduced size specifically in tumors will be better retained and/or penetrated in tumors than conventional non-adaptive NPs, and tumor accumulation of such NPs will be actively increased by targeted irradiation that results in local increase of microvascular permeability. The ra- tionale for this project is that its successful completion will enable the delivery of a greater amount of anti- cancer therapeutics to solid tumors than currently achieved with existing technology, thereby enhancing the effectiveness of cancer therapy. We will achieve our objective by pursuing the following three specific aims, where we will optimize the synthesis of ENPs and encapsulation of a model anti-cancer drug, paclitaxel (PTX) (Aim 1) and validate the IGRIP effect in a mouse model of prostate cancer (PCa) and optimize the irradiation regimen for NP delivery (Aim 2). Based on the optimized ENPs and irradiation regimen, we will correlate the pharmacokinetics and biodistribution of PTX delivery and anti-tumor effects in mice with PCa, to test the effec- tiveness of ENPs in PTX delivery to tumors as compared to Abraxane and the IGRIP enhancement of ENP delivery (Aim 3). By the completion of this study, we expect to have confirmed our approach as a valid meth- odology to increase biodistribution of nanomedicine into solid tumors and enhance therapeutic potential.

Public Health Relevance

The proposed research is relevant to public health because a drug delivery strategy that increases deposition of nanomedicine in tumors to a greater extent than currently possible can enhance the efficacy of chemotherapy, minimize systemic side effects, prolong patient survival and improve their quality of life. There- fore, this research is consistent with the mission of the NIH, which pertains to developing resources that will assure the Nation's capability to efficiently prevent and/or treat human diseases.

National Institute of Health (NIH)
Research Project (R01)
Project #
Application #
Study Section
Nanotechnology Study Section (NANO)
Program Officer
Tucker, Jessica
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Purdue University
Schools of Pharmacy
West Lafayette
United States
Zip Code
Park, Jinho; Park, Joonyoung; Pei, Yihua et al. (2016) Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines. Adv Drug Deliv Rev 104:93-109
Park, Jinho; Kadasala, Naveen Reddy; Abouelmagd, Sara A et al. (2016) Polymer-iron oxide composite nanoparticles for EPR-independent drug delivery. Biomaterials 101:285-95
Yeo, Yoon; Kim, Bieong-Kil (2015) Drug Carriers: Not an Innocent Delivery Man. AAPS J 17:1096-104
Cho, Eun Jung; Sun, Bo; Doh, Kyung-Oh et al. (2015) Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer. Biomaterials 37:312-9
Lee, Jinhyun Hannah; Yeo, Yoon (2015) Controlled Drug Release from Pharmaceutical Nanocarriers. Chem Eng Sci 125:75-84
Abouelmagd, Sara A; Sun, Bo; Chang, Alice C et al. (2015) Release kinetics study of poorly water-soluble drugs from nanoparticles: are we doing it right? Mol Pharm 12:997-1003
Abouelmagd, Sara A; Ku, Youn Jin; Yeo, Yoon (2015) Low molecular weight chitosan-coated polymeric nanoparticles for sustained and pH-sensitive delivery of paclitaxel. J Drug Target 23:725-35
Abouelmagd, Sara A; Hyun, Hyesun; Yeo, Yoon (2014) Extracellularly activatable nanocarriers for drug delivery to tumors. Expert Opin Drug Deliv 11:1601-18
Park, Joonyoung; Brust, Tarsis F; Lee, Hong Jae et al. (2014) Polydopamine-based simple and versatile surface modification of polymeric nano drug carriers. ACS Nano 8:3347-56